Document Detail


The cost of implantable defibrillators: perceptions and reality.
MedLine Citation:
PMID:  16887857     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: Recent guidelines have recommended more wide-ranging indications for the use of implantable cardioverter defibrillator (ICD) therapy, yet even more restrained previous guidelines have not been implemented for a variety of reasons. METHODS AND RESULTS: This brief review critically examines the reasons most frequently put forward to explain this failure. Contrary to the frequently repeated speculation that the risk stratification for sudden death and hence prophylactic placement of ICDs is reasonably accurate, there is little cost difference between pharmacotherapy and ICD treatment over the long term. ICD therapy does not utilize an undue proportion of the healthcare budget, and the healthcare systems in Europe can afford this therapy. CONCLUSION: Financial reasons are neither accurate nor adequate explanations for the failure of the European medical community to implement European guidelines for the implantation of ICDs for primary and secondary prevention of sudden cardiac death.
Authors:
John Camm; Helmut Klein; Seah Nisam
Related Documents :
20456647 - Recurrent implantable cardioverter-defibrillator replacement is associated with an incr...
16000917 - Implantable cardioverter defibrillator therapy.
22492677 - Functional biomaterials for cartilage regeneration.
1279587 - The measurement of the paced depolarization integral using the braided endocardial lead.
18401287 - The impact of cochlear implants from the perspective of significant others of adult coc...
17209827 - Dynamic recording of irrigating fluid distribution in root canals using thermal image a...
Publication Detail:
Type:  Journal Article; Review     Date:  2006-08-03
Journal Detail:
Title:  European heart journal     Volume:  28     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-16     Completed Date:  2007-11-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  392-7     Citation Subset:  IM    
Affiliation:
St George's University of London, Cranmer Terrace, London SW17 0RE, UK. jcamm@sgul.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Agents / economics
Cost-Benefit Analysis
Death, Sudden, Cardiac / prevention & control*
Defibrillators, Implantable / economics*
Drug Costs
Health Expenditures
Humans
Quality-Adjusted Life Years
Chemical
Reg. No./Substance:
0/Cardiovascular Agents
Comments/Corrections
Comment In:
Eur Heart J. 2007 Feb;28(4):386-7   [PMID:  17289746 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS.
Next Document:  Pride, prejudice, and paediatrics (women paediatricians in England before 1950).